Last reviewed · How we verify
CKD-11101
CKD-11101 is a novel therapeutic agent in phase 3 development by Chong Kun Dang Pharmaceutical with a mechanism not yet publicly disclosed.
At a glance
| Generic name | CKD-11101 |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
Limited public information is available regarding the specific mechanism of action for CKD-11101. As a phase 3 candidate from a South Korean pharmaceutical company, it is likely a small molecule or biologic targeting a specific disease pathway, but the exact molecular target and therapeutic mechanism require access to clinical trial data or company disclosures.
Approved indications
Common side effects
Key clinical trials
- CKD-11101 Phase 3 SC Study (PHASE3)
- CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis (PHASE3)
- Pharmacokinetics Study of CKD-11101 and NESP After SC Administration in Health Male Volunteers (PHASE1)
- Pharmacokinetics Study of CKD-11101 and NESP After IV Administration in Health Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKD-11101 CI brief — competitive landscape report
- CKD-11101 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI